NASDAQ:AXSM - Axsome Therapeutics Stock Price, Forecast & News

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Axsome Therapeutics Inc (NASDAQ:AXSM) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.56) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.15. View Axsome Therapeutics' Earnings History.

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Axsome Therapeutics.

10 Wall Street analysts have issued 12-month price objectives for Axsome Therapeutics' stock. Their forecasts range from $25.00 to $200.00. On average, they expect Axsome Therapeutics' stock price to reach $99.80 in the next year. This suggests a possible upside of 27.9% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axsome Therapeutics.

Press coverage about AXSM stock has been trending very negative on Saturday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Axsome Therapeutics earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Axsome Therapeutics.

Axsome Therapeutics saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 3,990,000 shares, a decline of 20.7% from the January 15th total of 5,030,000 shares. Based on an average trading volume of 1,320,000 shares, the short-interest ratio is currently 3.0 days. Approximately 13.9% of the shares of the stock are sold short. View Axsome Therapeutics' Current Options Chain.

Some companies that are related to Axsome Therapeutics include Elanco Animal Health (ELAN), Beigene (BGNE), Mylan (MYL), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD) and Reata Pharmaceuticals (RETA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), NVIDIA (NVDA), Alibaba Group (BABA), Sarepta Therapeutics (SRPT), Viking Therapeutics (VKTX), Netflix (NFLX), AbbVie (ABBV) and AT&T (T).

(AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Alethea Capital Management LLC (2.90%), Iridian Asset Management LLC CT (1.90%), State Street Corp (1.82%), Farallon Capital Management LLC (1.28%), Geode Capital Management LLC (1.07%) and RA Capital Management L.P. (1.07%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View Institutional Ownership Trends for Axsome Therapeutics.

AXSM stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Alethea Capital Management LLC, RA Capital Management L.P., State Street Corp, Schonfeld Strategic Advisors LLC, EAM Investors LLC, Royce & Associates LP and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Axsome Therapeutics.

AXSM stock was purchased by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, FMR LLC, Driehaus Capital Management LLC, Goldman Sachs Group Inc., Pictet Asset Management Ltd., Renaissance Technologies LLC, Farallon Capital Management LLC and New York State Common Retirement Fund. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad and Nick Pizzie. View Insider Buying and Selling for Axsome Therapeutics.

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXSM stock can currently be purchased for approximately $78.00.

Axsome Therapeutics has a market capitalization of $2.69 billion. The company earns $-30,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.View Additional Information About Axsome Therapeutics.

The official website for Axsome Therapeutics is http://axsome.com/.

Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.